Changing the Perspective on Cardiac Amyloidosis:
From Missed and Undiagnosed, to Common and Treatable!

7:00 PM – 9:00 PM     Sunday, September 16, 2018
Gaylord Opryland Hotel & Convention Center, Tennessee C Ballroom     Nashville, TN

Program Co-Chairs
Martha Grogan, MD (Co-Chair)
Assistant Professor of Medicine
Consultant, Division of Cardiovascular Diseases
Director, Cardiac Amyloid Clinic
Mayo Clinic
Rochester, MN

Mathew S. Maurer, MD (Co-Chair)
Professor of Medicine
Arnold and Arlene Goldstein Professor of Cardiology
Director, Clinical Cardiovascular Research Laboratory for the Elderly
Columbia University Medical Center / New York Presbyterian Hospital
New York, NY

Faculty
Mazen Hanna, MD
Co-Director, Amyloidosis Center
Section of Heart Failure and Cardiac Transplant Medicine
Cleveland Clinic
Cleveland, OH

Daniel P. Judge, MD
Professor of Medicine
Director, Cardiovascular Genetics
Director, Adult Cardiology Fellowship Program
Medical University of South Carolina
Charleston, SC

Jose Nativi-Nicolau, MD, MSCI
Assistant Professor of Medicine
Director, Cardiovascular Medicine Intensive Care Unit
Director, Cardiac Amyloidosis Program
Heart Failure and Transplant Cardiology
University of Utah
Salt Lake City, UT

Ronald M. Witteles, MD
Associate Professor of Medicine, Division of Cardiovascular Medicine
Co-Director, Stanford Amyloid Center
Program Director, Internal Medicine Residency Training Program
Stanford University School of Medicine
Stanford, CA

Patient Panel
Isabelle Lousada (Moderator)
CEO & President
Amyloidosis Research Consortium
Newton, MA

Cecelia Beckwith
Portland, OR

Learning Objectives
Following this activity, participants will be able to:
- Define amyloidosis, including specific types and their cardiac features.
- Identify barriers to patient identification and accurate diagnosis.
- Propose mechanisms to increase awareness of amyloidosis amongst heart failure providers and referring physicians.
- Discuss the importance of early diagnosis and timely referral to expert resources.
- Outline current and emerging treatments available for patients with different types of cardiac amyloidosis.
- Identify the need for ongoing assessment of the effectiveness of treatments and when to consider alternate treatments.

Symposium Agenda
7:00 PM   Welcome and ARS Questions
Martha Grogan
Mathew S. Maurer (Co-Chairs)

7:05 PM   Cardiac Amyloidosis from the Patient Perspective
Patient Panel

7:35 PM   Definitive Diagnosis: Get it right!
Mazen Hanna
Daniel P. Judge

8:05 PM   Emerging Treatments: Coming NOW
Ronald M. Witteles
Jose Nativi-Nicolau

8:35 PM   Rapid Fire Case Studies
Co-Chairs and Faculty

8:50 PM   Wrap Up, Final Audience Q&A

9:00 PM   Session Adjourns

Accreditation
Physicians:
Accreditation statement: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Heart Failure Society of America designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:
Information on continuing nursing credit (CNE) will be provided to participants during the symposium.

Eligibility
Registration for the 22nd Annual Scientific Meeting and an official name badge are required to attend this symposium.

Supported by independent medical education grants from the Amyloidosis Research Consortium and Pfizer

HFSA
Heart Failure Society of America
Accredited Sponsor: Heart Failure Society of America